Navidea to Hold Conference Call to Provide Investor Update on Status of Ongoing Corporate Events
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today announced that management will hold an audio webcast conference call on Tuesday, January 31, 2017 at 4:30 p.m. to provide investor update on status of ongoing corporate events. A business update will follow the closing of the Cardinal Health transaction.
Investors and the public are invited to access the live audio webcast through the link below. Participants are encouraged to log-in and or/dial-in fifteen minutes before the conference begins. The webcast replay is expected to be available on our investor website, http://ir.navidea.com, approximately two to four hours after the live event.
|Event:||Navidea Biopharmaceuticals Business Update Call|
|Date/Time:||January 31, 2017; 4:30 p.m. ET|
|Dial-In Number – US:||(855) 897-5884|
|Dial-In Number – Int’l:||(720) 634-2940|
|Conference ID Number:||63292587|
A webcast replay will be available on the Investor Relations section of our website at http://ir.navidea.com for 30 days.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products and platforms including Manocept™ and NAV4694 to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s first commercial product from the Manocept platform, was approved by the FDA in March 2013 and in Europe in November 2014. The development activities of the Manocept immunotherapeutic platform will be conducted by Navidea in conjunction with its subsidiary, Macrophage Therapeutics. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit www.navidea.com.
Investors & Media
Jed Latkin, COO & CFO, 614-973-7490
Source: Navidea Biopharmaceuticals, Inc.
Released January 27, 2017